The phase II segment of the company's Inovio INO-4800 Vaccine Trial for Efficacy (INNOVATE) trial, which is still on clinical hold in the U.S., showed that a 2-mg dose of the vaccine, INO-4800, was effective and well tolerated in 400 participants across a range of ages, the company said.

Inovio will file the phase II results with the U.S. Food and Drug Administration (FDA) to address the agency's questions about the Cellectra 2000 device used to deliver INO-4800. Once the FDA has given the go-ahead, Inovio will begin its phase III portion of the trial.

The trial has been funded by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency, according to the firm.

Inovio will not conduct phase III COVID-19 vaccine trial in U.S.
Inovio announced it is planning for a phase III trial outside of the U.S. for its INO-4800 COVID-19 vaccine candidate after the U.S. Department of Defense...

Inovio's COVID-19 vaccine is protective against variants of concern
Inovio has announced promising results from a study focusing on the human immune responses induced by its DNA vaccine candidate for COVID-19, INO-4800.

Inovio to develop COVID-19 DNA-encoded monoclonal antibodies
Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a...

Inovio expands COVID-19 vaccine manufacturing with Kaneka
Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800,...

Inovio begins late phase clinical trials for COVID-19 vaccine
Inovio has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the phase II segment of its phase II/III clinical trial...